The key industry bodies from across Europe have signed a letter to UK Brexit minister David Davis and EU chief Brexit negotiator Michel Barnier saying the UK must stay in the European Medicines Agency system
It’s a virtuous circle: New approval processes put in place by the European Medicines Agency are de-risking drug development, promoting investment in early-stage biotech and meeting unmet medical needs, says Paul Morton
At the fourth time of asking, the European Medicines Agency is recommending approval of Glybera, opening up a new era in the treatment of rare diseases, and unlocking the wider potential of gene therapy
The European Medicines Agency’s thumbs-down for rare disease treatment Glybera flies in the face of Commission policy. It’s also against the wishes of the European Parliament, and the impetus DG Sanco is putting into Orphan Drugs. Worse still, it’s bad for patients and kills innovation. By Nuala Moran.
Despite industry’s endless lip service to driving innovation for the benefit of patients, many diseases go untreated. Now, sick of being passive recipients, patients are taking control and shaping innovation to their real needs